ES2142848T3 - E-coli p-fimbrina como sistema portador inmunogenico contra gnrh. - Google Patents

E-coli p-fimbrina como sistema portador inmunogenico contra gnrh.

Info

Publication number
ES2142848T3
ES2142848T3 ES93201712T ES93201712T ES2142848T3 ES 2142848 T3 ES2142848 T3 ES 2142848T3 ES 93201712 T ES93201712 T ES 93201712T ES 93201712 T ES93201712 T ES 93201712T ES 2142848 T3 ES2142848 T3 ES 2142848T3
Authority
ES
Spain
Prior art keywords
coli
fimbrine
carrier system
system against
immunogenic carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93201712T
Other languages
English (en)
Spanish (es)
Inventor
Der Zee Anna Van
Die Irma Marianne Van
Willem Pieter Martin Hoekstra
Josephus Theodorus Gielen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2142848T3 publication Critical patent/ES2142848T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gyroscopes (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES93201712T 1992-06-18 1993-06-15 E-coli p-fimbrina como sistema portador inmunogenico contra gnrh. Expired - Lifetime ES2142848T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92201775 1992-06-18
EP93201712A EP0578293B1 (en) 1992-06-18 1993-06-15 E-coli P-fimbrine as immunogenic carrier system against GnRH

Publications (1)

Publication Number Publication Date
ES2142848T3 true ES2142848T3 (es) 2000-05-01

Family

ID=8210697

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93201712T Expired - Lifetime ES2142848T3 (es) 1992-06-18 1993-06-15 E-coli p-fimbrina como sistema portador inmunogenico contra gnrh.

Country Status (18)

Country Link
US (2) US5684145A (https=)
EP (1) EP0578293B1 (https=)
JP (1) JPH0656696A (https=)
KR (1) KR100293025B1 (https=)
AT (1) ATE188737T1 (https=)
AU (1) AU667715B2 (https=)
BR (1) BR9302408A (https=)
CA (1) CA2098533C (https=)
DE (1) DE69327553T2 (https=)
DK (1) DK0578293T3 (https=)
ES (1) ES2142848T3 (https=)
GR (1) GR3033086T3 (https=)
HU (1) HU217096B (https=)
MX (1) MX303646A (https=)
NZ (1) NZ247907A (https=)
PT (1) PT578293E (https=)
TW (1) TW240232B (https=)
ZA (1) ZA934199B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
ATE191147T1 (de) * 1991-07-26 2000-04-15 Commw Scient Ind Res Org System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995020657A1 (en) * 1994-01-27 1995-08-03 Gx Biosystems A/S Receptor specific bacterial adhesins and their use
US6635740B1 (en) * 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US6013770A (en) * 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DK1035133T3 (da) * 1999-02-17 2005-05-02 Pfizer Prod Inc Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1303533A2 (en) * 2000-05-05 2003-04-23 Aphton Corporation Chimeric peptide immunogens, their preparation and use
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
EP1432443B1 (en) * 2001-10-05 2009-01-21 Cytos Biotechnology AG Angiotensin peptide-carrier conjugates and uses thereof
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
NZ220932A (en) * 1986-07-03 1990-05-28 Victoria State Composition comprising an antigenic substance, such as lhrh, conjugated to at least two different carriers and method of immunological castration and spaying
EP0264150B1 (fr) * 1986-10-13 1993-01-07 Solvay Microorganismes comportant des pili comme protéines porteuses, pili isolés à partir de ces microorganismes, procédé d'excrétion de peptides ou de protéines à l'aide de ces pili et utilisation de ceux-ci
WO1988008430A1 (en) * 1987-04-27 1988-11-03 Commonwealth Scientific And Industrial Research Or Peptide production by protein engineering
EP0314224B1 (en) * 1987-10-26 1992-05-27 Akzo N.V. Vaccine against e.coli septicaemia in poultry
US5036047A (en) * 1988-09-29 1991-07-30 Pitman-Moore, Inc. Method and composition for preventing conception
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
NL8900726A (nl) * 1989-03-23 1990-10-16 Stichting Centr Diergeneeskund Peptide, immunogene samenstelling en vaccin- of geneesmiddelpreparaat; werkwijze voor het immuniseren van een zoogdier tegen lhrh, en werkwijze voor het verbeteren van de vleeskwaliteit van varkens.

Also Published As

Publication number Publication date
MX303646A (es) 1994-05-31
AU4134393A (en) 1993-12-23
ZA934199B (en) 1994-01-10
US6019983A (en) 2000-02-01
EP0578293B1 (en) 2000-01-12
TW240232B (https=) 1995-02-11
CA2098533A1 (en) 1993-12-19
CA2098533C (en) 2005-08-16
PT578293E (pt) 2000-06-30
HUT68554A (en) 1995-06-28
HU9301764D0 (en) 1993-10-28
JPH0656696A (ja) 1994-03-01
KR100293025B1 (ko) 2001-09-17
BR9302408A (pt) 1994-01-11
DE69327553T2 (de) 2000-08-10
DK0578293T3 (da) 2000-06-26
EP0578293A1 (en) 1994-01-12
HU217096B (hu) 1999-11-29
AU667715B2 (en) 1996-04-04
NZ247907A (en) 1994-12-22
GR3033086T3 (en) 2000-08-31
US5684145A (en) 1997-11-04
ATE188737T1 (de) 2000-01-15
KR940000115A (ko) 1994-01-03
DE69327553D1 (de) 2000-02-17

Similar Documents

Publication Publication Date Title
ES2142848T3 (es) E-coli p-fimbrina como sistema portador inmunogenico contra gnrh.
MX9700211A (es) Derivados novedosos de purinilo substituidos con actividad inmunomoduladora.
NO982497L (no) Vaksine-sammensetninger for inntak gjennom nesen
PT642581E (pt) Vacinas de clostridium perfringens
EP0789593A4 (en) Yeast-based delivery vehicles
NO943920D0 (no) Vaksineadjuvans
ES2084827T3 (es) Composiciones de vacuna mejoradas.
DK0741744T3 (da) Immunogener mod gonadeotropinfrigørende hormon
ES2192582T3 (es) Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado.
AU1013701A (en) Modified gp100 and uses thereof
NZ333226A (en) Immunstimulating lipid formulation
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
ES2051862T3 (es) Un metodo para producir un medicamento que tiene un efecto catartico.
ES2127761T3 (es) Vacuna contra la dermatomicosis.
ES2124701T3 (es) Composiciones de vacunas.
AR022758A1 (es) Vacunas
WO1999020305A8 (en) Veterinary vaccines
IL122829A (en) Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
AU1227700A (en) Method for the production of purified invasin protein and use thereof
ATE84722T1 (de) Tollwut-lebendimpfstoff.
DE60045516D1 (de) Pflanzen lektine als mukosale adjuvantien
GB2358352A (en) Bacterial extract as oral adjuvant
DE60022995D1 (de) Impfstoff
MX9705082A (es) Composiciones para el suministro de antigenos.
BR1100629A (pt) Sistema de veìculo imunogênico capaz de dar uma resposta imune contra gnrh, um análogo ou um derivado de gnrh, sequência de dna recombinante, vetor de expressão, microorganismo e vacina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 578293

Country of ref document: ES